Raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A study protocol

B.A. Brand, J.N. de Boer, S.B.J.O. Ophuis, M.I.E. Slot, B. De Wilde, K.C.E.E.R. Catthoor, A.J. Goverde, P.R. Bakker, M.C. Marcelis, K.P. Grootens, J.J. Luykx, S.M. Heringa, C.S. Weickert, I.E.C. Sommer, T.W. Weickert

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number100681
Number of pages8
JournalContemporary Clinical Trials Communications
Volume20
DOIs
Publication statusPublished - 1 Dec 2020

Keywords

  • antipsychotic medication
  • cognition
  • double-blind
  • estrogen
  • negative syndrome
  • performance
  • persistent symptoms
  • postmenopausal women
  • raloxifene
  • randomised controlled trial
  • reliability
  • scale
  • schizophrenia
  • sex-differences
  • PERFORMANCE
  • Estrogen
  • Schizophrenia
  • RELIABILITY
  • SCALE
  • POSTMENOPAUSAL WOMEN
  • PERSISTENT SYMPTOMS
  • NEGATIVE SYNDROME
  • COGNITION
  • Antipsychotic medication
  • Randomised controlled trial
  • DOUBLE-BLIND
  • ESTROGEN
  • Raloxifene
  • SEX-DIFFERENCES

Cite this